Pfizer Alzheimer’s Disease Drug Fails in Study

Pfizer Inc. said Wednesday that its Alzheimer’s drug candidate Dimebon did not meet its goal in a late stage clinical study, as the drug was no better than a placebo at treating the disease.

The compound Dimebon did not meet any of its main or secondary goals in the study, which involved 598 patients with mild to moderate Alzheimer’s disease. Dimebon is considered one of Pfizer’s key drug candidates and the company is running four other late stage trials of the drug.